

CORRECTION

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Guy Neff¹ · Woodie Zachry III²

Published online: 1 June 2018
© The Author(s) 2018

Correction to: PharmacoEconomics
<https://doi.org/10.1007/s40273-018-0641-6>

The article Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin written by Guy Neff, Woodie Zachry was originally published electronically on the publisher's internet portal (currently Springer Link) on April 12, 2018 without open access.

With the author(s)' decision to opt for Open Choice the copyright of the article changed on May 31, 2018 to © The Author(s) [2018] and the article is forthwith distributed under the terms of the Creative Commons Attribution- Non Commercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation,

distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license and any changes made are indicated.

Open Access This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40273-018-0641-6>.

✉ Guy Neff
guy.neff@fdhs.com

¹ Florida Research Institute, Florida Digestive Health Specialists, Lakewood Ranch, FL, USA

² Quantym Therapeutic Data, Sarasota, FL, USA